(firstQuint)Phase 3, Febuxostat, Allopurinol and Placebo-Controlled Study in Gout Subjects.

.

 A Phase 3 Study comparing 80 mg, 120 mg or 240 mg of febuxostat, allopurinol (300 mg for those with normal renal function and 100 mg for those with impaired renal function) and placebo administered once daily in subjects with gout.

 Subjects will receive treatment for 28 weeks.

.

 Phase 3, Febuxostat, Allopurinol and Placebo-Controlled Study in Gout Subjects.

@highlight

The purpose of this study is to compare febuxostat, allopurinol and placebo, once daily (QD), in subjects with gout.

